Psychosis reactivity to cannabis use in daily life: an experience sampling study
Cécile Henquet, Jim van Os, Rebecca Kuepper, Philippe Delespaul, Maurice Smits, Joost Á Campo, Inez Myin-Germeys
The British Journal of Psychiatry May 31, 2010 DOI: 10.1192/bjp.bp.109.072249 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Observational cohort Peer reviewed |
|---|---|
| Sample size | 80 |
| Population | Patients with psychotic disorder and healthy controls |
| Topics | Cannabis |
| Citations | 124 |
| Key findings | Cannabis use predicted increased positive affect in both groups and decreased negative affect only in patients. In patients, but not controls, cannabis predicted increased hallucinatory experiences. Mood effects were acute; psychosis effects were sub-acute, with no direct self-medication evidence. |
Abstract
Background: Little is known about the experiential dynamics of the interaction between cannabis and vulnerability to psychosis.
Aims: To examine the effects of cannabis on psychotic symptoms and mood in patients with psychosis and healthy controls.
Method: Patients with a psychotic disorder (n = 42) and healthy controls (n = 38) were followed in their daily lives using a structured time-sampling technique.
Results: Daily life cannabis use predicted subsequent increases in positive affect and in patients, but not in controls, decreases in negative affect. In patients, but not in controls, cannabis use predicted increased levels of hallucinatory experiences. Mood-enhancing properties of cannabis were acute, whereas psychosis-inducing effects were sub-acute. There was no direct evidence for self-medication effects in daily life.
Conclusions: Patients with psychosis are more sensitive to both the psychosis-inducing and mood-enhancing effects of cannabis. The temporal dissociation between acute rewarding effects and sub-acute toxic influences may be instrumental in explaining the vicious circle of deleterious use in these patients.
Comparable studies
Other observational and cohort studies on cannabis, most cited first.
| Study | Year | Design | Participants |
|---|---|---|---|
| High-potency cannabis and the risk of psychosis People with first episode of psychosis and healthy controls from the local population | 2009 | Case-control study | n = 454 |
| Ayahuasca-Assisted Therapy for Addiction: Results from a Preliminary Observational Study in Canada Rural aboriginal population | 2013 | Observational study | |
| Impaired cognitive performance in drug free users of recreational ecstasy (MDMA) Otherwise healthy young people | 2000 | Observational | |
| Continued cannabis use and risk of incidence and persistence of psychotic symptoms: 10 year follow-up cohort study Individuals from the general population in Germany aged 14-24 at baseline | 2011 | Observational cohort | n = 1,923 |
| Cannabis-induced psychosis and subsequent schizophrenia-spectrum disorders: follow-up study of 535 incident cases Patients treated for cannabis-induced psychotic symptoms in Denmark between 1994 and... | 2005 | Observational cohort | n = 535 |
Citations in the library
Cited by 22
- Gone to Pot – A Review of the Association between Cannabis and Psychosis Frontiers in Psychiatry May 22, 2014
- Association Between Continued Cannabis Use and Risk of Relapse in First-Episode Psychosis JAMA Psychiatry September 28, 2016
- Unraveling the Intoxicating and Therapeutic Effects of Cannabis Ingredients on Psychosis and Cognition Frontiers in Psychology May 14, 2020
- Psychedelic symptoms of cannabis and cocaine use as a function of trait impulsivity Journal of Psychopharmacology January 8, 2015
- Does cannabidiol protect against the negative effects of THC? The British Journal of Psychiatry September 30, 2010
and 17 more in the library
Cites 11
- Causal association between cannabis and psychosis: examination of the evidence The British Journal of Psychiatry January 30, 2004
- High-potency cannabis and the risk of psychosis The British Journal of Psychiatry November 30, 2009
- From dopamine to salience to psychosis--linking biology, pharmacology and phenomenology of psychosis. Schizophrenia Research November 1, 2005
- Opposite effects of delta-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology. Neuropsychopharmacology November 18, 2009
- Delta 9-tetrahydrocannabinol induces dopamine release in the human striatum. Neuropsychopharmacology February 2009
and 6 more in the library